Diagnosing impaired glucose tolerance using direct infusion mass spectrometry of blood plasma

PLoS One. 2014 Sep 9;9(9):e105343. doi: 10.1371/journal.pone.0105343. eCollection 2014.

Abstract

The goal of this study was to evaluate the capacity for mass spectrometry of blood plasma to diagnose impaired glucose tolerance (IGT). For this study, blood plasma samples from control subjects (n = 30) and patients with IGT (n = 20) were treated with methanol and low molecular weight fraction were then analyzed by direct infusion mass spectrometry. A total of 51 metabolite ions strongly associated with IGT were detected. The area under a receiver operating characteristic (ROC) curve (AUC) for diagnosing IGT that was based on an analysis of all these metabolites was 0.93 (accuracy 90%, specificity 90%, and sensitivity 90%). The associated reproducibility was 85%. The metabolites identified were also consistent with risk factors previously associated with the development of diabetes. Thus, direct infusion mass spectrometry of blood plasma metabolites represents a rapid, single-step, and reproducible method for the analysis of metabolites. Moreover, this method has the potential to serve as a prototype for clinical analyses that could replace the currently used glucose tolerance test with a more patient-friendly assay.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Glucose Intolerance / blood*
  • Glucose Intolerance / diagnosis*
  • Humans
  • Male
  • Mass Spectrometry*
  • Metabolomics / methods*
  • Middle Aged
  • Plasma / chemistry*
  • Prediabetic State / blood
  • Prediabetic State / diagnosis

Grants and funding

This work was supported by the Russian Academy of Medical Science (‘Human Proteome Program, Medical Addendum’) and Russian Academy of Science (grant ‘Metabolomics-based diagnostics of impaired glucose tolerance’). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.